<b>Full Title</b><br> F8294-201b: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations <br><br> <b>Study Treatment</b><br> Oral BRAF inhibitor FORE8394 in combination with cobicistat <br><br> <b>Eligibility/Info</b><br> For the treatment of patients with a BRAF V600E mutant CNS primary malignancy that has recurred or continued to grow after at least 1 prior line of therapy including radiation. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>.